Grifols Therapeutics LLC

Grifols Egypt for Plasma Derivatives (GEPD) is a public-private joint venture between Egypt's National Service Projects Organization and Grifols, the global healthcare leader. GEPD develops and manufactures plasma-derived medicines to achieve Egypt's clinical self-sufficiency in critical biological therapies. The company has established commercial production of three core plasma derivatives: immunoglobulins (immune globulins), human albumin, and coagulation factors for bleeding disorders. This achievement positions Egypt as the sixth country globally capable of domestic plasma derivative manufacturing. GEPD operates 16 plasma donation centers across Egypt with expansion planned to 20 centers by 2026, supported by European Medicines Agency (EMA) certification enabling export to European markets. The company supplies safe, pharmaceutical-grade plasma-derived medicines to Egyptian public hospitals and health institutions, directly supporting healthcare infrastructure modernization and reducing dependence on imported biological therapeutics.